Cefotetan in Cancer Therapy
- Overview
Brief Description: Cefotetan is an FDA-approved antibiotic being repurposed for targeting b hCG in BRCA1 defective breast cancers, addressing significant challenges in cancer treatment and potential drug resistance.
Development Stage: The technology is in the preclinical testing phase, with promising results from in vitro studies and further research needed before clinical applications.
- Key Features
- Cefotetan demonstrates selective cytotoxic effects in BRCA1 defective cell lines, indicating its potential as a targeted treatment.
- Being an FDA-approved antibiotic, cefotetan has a well-documented safety and pharmacokinetic profile.
- Advanced computational methods have identified specific binding sites and interactions between cefotetan and bhCG, supporting its therapeutic potential.
- Benefits:
- Economic Impact: Potential to reduce healthcare costs associated with ineffective treatments and enhance patient outcomes in BRCA1 related cancers.
- Social Impact: Improved treatment options for patients with limited responses to traditional therapies, promoting better quality of life and survival rates.
- Environmental Impact: Repurposing existing drugs helps to streamline development efforts and reduce waste in pharmaceutical production.
- Applications:
- Utilized in treating breast cancers, particularly those associated with BRCA1 mutations.
- Further research could explore combinatorial therapies and refine methodologies for targeting bhCG pathways in other cancer types.
- Case Studies:
- In vitro testing showed cefotetan reduced cell proliferation in BRCA1 hypermethylated cell lines by over 50% in MTT assays.
- Binding studies confirmed significant interaction between cefotetan and bhCG, supporting its use as a promising therapeutic agent.
- IP Status:
- Intellectual Property: Provisional patent filed in USA vide 63/799,963 dated 5 May, 2025
- Support Offered:
- Licensing Options: Opportunities for licensing the use of cefotetan in cancer therapy may be available to pharmaceutical companies.
- Technical Support: Comprehensive research documentation and findings are provided to support further studies and application development.
- Collaboration Opportunities: Open to partnerships for continued research and development in cancer therapeutics.
- Contact Information:
Contact Person: Dr. Priya Srinivas, Scientist, BRIC-RGCB
Email Address: priyasrinivas@rgcb.res.in,techventures@rgcb.res.in
Phone Number: